An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

The maintenance dose of Ozempic for weight loss is usually 1.0 mg per week. Some individuals may require an increase to 2.0 mg if recommended by their healthcare provider. Always adhere to the ...

The ULs for each nutrient remain unchanged from the 3rd edition values: 100 mg/day for vitamin B6, 1,000 mg (1,600 IU)/day ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo ... 3 Semaglutide has been approved by the FDA in both long-acting injectable (Wegovy and Ozempic) and daily oral tablet ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Gradually increased to a maximum dose of 2.0 mg weekly. Common side effects include nausea, vomiting, diarrhea, and constipation. Consult your healthcare provider or the Ozempic medication guide ...

The FDA's approval is based on the results of the FLOW phase 3b kidney outcomes trial. The trial revealed that Ozempic® 1 mg significantly lowered the relative risk of worsening kidney disease, kidney ...

establishes Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg as the most broadly indicated glucagon-like peptide-1 receptor agonist (GLP-1 RA) in its class," the Danish drugmaker said.